Peli

Quick links to important sections

Peli

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peli

Property Description
Active ingredient Buflomedil hydrochloride
Form Oral tablets, Injectable solutions
Pharmacological class Peripheral vasodilator, Vasoactive agent
General Purpose To improve circulation in the extremities
Origin Synthetic small molecule

Peli: A Synthetic Vasoactive Peripheral Vasodilator

Peli is the trade name for a medication whose sole active component is the synthetic chemical substance Buflomedil hydrochloride. This substance is classified as a vasoactive agent, belonging to the subgroup of peripheral vasodilators. This classification is consistently recognized in pharmacological systems, including the World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system. Buflomedil acts as an alpha adrenergic receptor inhibitor, a specific mechanism clinically recognized for reducing resistance in peripheral blood vessels.

Composition and Available Drug Forms

Buflomedil hydrochloride is provided as a single-ingredient product, simplifying its composition profile. This formulation is available in two principal dosage forms: oral tablets (typically film-coated) for continuous therapy and sterile injectable solutions for parenteral administration. The availability of both oral and injectable preparations is a distinguishing feature, historically allowing for therapeutic continuity between acute treatment (using intravenous injection or intramuscular injection) and ongoing maintenance with the tablets. The efficacy of Buflomedil in improving blood flow has been supported by pharmacological studies focused on peripheral arterial diseases.

The General Therapeutic Purpose of Buflomedil

The medication’s fundamental purpose is centered on enhancing tissue perfusion in the extremities where circulation is restricted. Its function is to facilitate the flow of oxygen and essential nutrients to affected areas. It achieves this through a dual mechanism principle: initiating vasodilation to widen constricted vessels and acting as a hemorheologic agent by improving the mechanical properties of blood, such as red blood cell flexibility. This combined action offers a general benefit for individuals experiencing symptoms related to insufficient peripheral circulation.

Regulatory References

  1. BfArM Risk Information on Buflomedil

What side effects are possible with Peli?

Possible Side Effects and Safety Information

The regulatory safety profile for Buflomedil hydrochloride (Peli) is primarily structured around the risk of Serious Adverse Events (SAEs) impacting key physiological systems, documented even when the medicine is used within the established therapeutic dosage range.


System-Organ Classes and Serious Reactions

Adverse events officially documented in regulatory sources fall into two main System-Organ Classes:

  • Nervous System Disorders: Documented serious reactions include convulsions, myoclonia, and status epilepticus.
  • Cardiac and Vascular Disorders: Documented serious reactions include cardiac arrest, ventricular rhythm disorders, tachycardia, and hypotension.

Less serious effects, such as hypertension and flushing, have also been documented in regulatory reports.


Population-Specific Safety and Restrictions

Safety data specifies that the risk of serious neurological and cardiac adverse events is heightened in older adults and in patients with renal impairment. The official regulatory text indicates a need for dose-adaptation based on kidney function.

  • Safety Restriction: Buflomedil is recognized as having a narrow therapeutic index, indicating a small margin between the effective and toxic dose. A contraindication in individuals with severe renal impairment is a formal safety requirement.

The overall safety framework is defined by the necessity to mitigate these officially documented, severe risks, which are a central focus of government safety assessments.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory assessments classify Peli (Buflomedil) intoxication as potentially life-threatening and associated with fatal outcomes, a risk reflecting the drug's narrow therapeutic margin. The official profile is based on findings from regulatory agencies, including the European Medicines Agency (EMA).

Documented Overdose Manifestations

Overdose is characterized by severe, abrupt effects on the Central Nervous System and Cardiovascular System. Documented manifestations include neurological events such as convulsions, status epilepticus, and myoclonia, alongside critical cardiovascular toxicity including cardiac arrest, ventricular rhythm disorders, and severe hypotension. The official profile also notes that elderly patients and those with renal impairment have a heightened risk of severe outcomes due to potential drug accumulation.

Emergency Actions and Management

Regulators mandate that patients or caregivers must seek immediate medical attention and effect the immediate discontinuation of the drug upon the onset of any severe symptom. Immediate medical help is required for life-threatening events such as status epilepticus or cardiac arrest.

Management relies strictly on symptomatic and supportive treatment, as official sources confirm that no specific antidote is known. Required procedures include close continuous cardiac and neurological monitoring under hospital observation. Supportive measures described include gastric lavage, activated charcoal, and the use of targeted pharmacological agents to control seizures.

Therapeutic Uses of Peli

Paliperidone (Peli) is used across therapeutic domains where additional symptomatic support is needed. The medication is indicated for the treatment of schizophrenia and schizoaffective disorder in adults, and may assist with the management of schizophrenia in adolescents.

Quick Fact: Relief for symptoms that interfere with daily functioning

This medicine is relevant for easing symptoms related to heightened physiological activity, particularly those that become disruptive during flare-ups. It is applied when symptoms create noticeable functional strain, such as thought disturbances or sensory changes, in conditions involving episodic or fluctuating manifestations.

Peli is commonly used to help with symptom clusters that involve recurrent or episodic manifestations. Applied in clinical settings that involve acute or unstable symptom patterns, the medication contributes to easing the overall symptom load. A key patient benefit is providing support that helps ease the overall symptom burden. “Offers symptomatic relief that helps patients cope more steadily.”

Eligibility and Restrictions for Use

Official Regulatory Eligibility and Restrictions

Official regulatory bodies define the eligible patient population for Peli (Paliperidone) through documented contraindications and restrictions based on age, organ function, and pre-existing conditions.

Classification Population Restriction
Absolute Contraindications Hypersensitivity to Paliperidone, Risperidone, or formulation excipients. Elderly patients with dementia-related psychosis (use is not approved due to increased mortality risk).
Age-Related Eligibility Established for use in Adults. Safety and effectiveness are not established in children under 12 years of age for schizophrenia or in the pediatric population for schizoaffective disorder.
Renal Function Status Use is generally not recommended in cases of severe renal impairment (creatinine clearance < 50 mL/min for injectable forms or < 10 mL/min for the oral form).
Reproductive Status Use during the third trimester of pregnancy is associated with the risk of extrapyramidal and/or withdrawal symptoms in newborns. Use while breastfeeding is generally not recommended due to excretion into breast milk.
Conditional Use Caution is required for patients with a history of seizures, known cardiovascular disease, Parkinson's disease, or conditions predisposing to hypotension (low blood pressure).

What should I know about interactions with other medicines?

The interaction profile for Peli (Paliperidone) is structured around official regulatory constraints derived from pharmacokinetic and pharmacodynamic findings. Exposure modification is a primary concern, as co-administration with other medicines can significantly alter the systemic concentration of Peli.

A strong restriction applies to strong CYP3A4 and P-glycoprotein (P-gp) inducers, such as carbamazepine. These inducers, including the herbal product St John's Wort, must be avoided during the entire dosing interval of the long-acting injectable formulations, as they are documented to reduce Peli's exposure. For instance, co-administration with carbamazepine is documented to decrease Peli's levels by approximately 37%. Conversely, co-administration with divalproex sodium is documented to increase Peli's concentration by approximately 50%.

Additive effects define the key pharmacodynamic interactions. Co-administration with other medicines that prolong the QT interval must be avoided. Similarly, an increased risk of orthostatic hypotension and CNS effects is documented when Peli is combined with agents that also cause these effects. The regulatory documentation requires that alcohol intake also be avoided due to the potential for additive central nervous system effects. Finally, for patients with renal impairment, interaction effects may be enhanced due to the documented slower clearance of Peli from the body.

Mechanism of Action

How Peli Works

Peli (Buflomedil) operates through a dual pharmacodynamic mechanism that modulates both vascular tone and the physical properties of the blood, leading to physiological adjustments in peripheral circulation.


Modulating Vascular Tone via Alpha-Receptor Antagonism

This mechanism involves the drug acting as a competitive antagonist of Alpha-1 Adrenoceptors (alpha1-AR) found on vascular smooth muscle cells. By preventing the binding of endogenous catecholamines like norepinephrine, Peli disrupts the sympathetic signaling cascade responsible for vasoconstriction. This interference facilitates the relaxation of vascular smooth muscle, primarily in arterioles and pre-capillary sphincters, and results in a functional reduction in peripheral vascular resistance.


Altering Blood Flow Dynamics (Hemorheology)

In addition to its vascular action, Peli targets the components of the blood itself. The molecule enhances the deformability (flexibility) of red blood cells and acts as an inhibitor of platelet aggregation, thereby decreasing the overall viscosity of the blood. This allows for greater ease of passage through narrow microvessels, resulting in enhanced tissue perfusion and nutrient exchange at the capillary level in the extremities.

Dosage and Administration Information

The usage of Peli, whose active component is Paliperidone, follows specific instructions to ensure consistent administration. The medication is available as an extended-release oral tablet and as an intramuscular (IM) injectable suspension, which determines the administration route.


Administration Protocol

Entity Administration Details
Route of Administration Oral ingestion; Intramuscular (IM) injection.
Dosing Schedule Standard adult oral starting dose is 6 mg once daily. The typical maintenance range is 3 mg to 12 mg per day, not to exceed 12 mg daily.
Frequency Pattern Oral tablets are taken once daily. Injectable forms follow a long-interval schedule (e.g., monthly, 3-monthly, or 6-monthly).
Ingestion Requirements Oral tablets must be swallowed whole and cannot be crushed, chewed, or divided to maintain their extended-release function. Dosing may be with or without food.

Procedural Constraints

There are several important procedural constraints that define the drug's use protocol. The oral formulation is typically intended for continuous, long-term administration. The preparation of injectable suspensions mandates vigorous shaking prior to professional administration. A critical requirement is the need for dose adjustment in patients with renal impairment. This modification is based on the patient's creatinine clearance, requiring a reduced starting dose (e.g., 3 mg once daily) to support consistency in administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Peli


Evidence for use in Symptomatic Chronic Peripheral Vascular Disease

Peli was evaluated in research exploring how symptoms change over time for people experiencing Intermittent Claudication. This condition was studied for outcomes related to physical discomfort in the legs during activity in Peripheral Arterial Disease (PAD). These studies include both short-term Randomized Controlled Trials (RCTs) and at least one large, long-term RCT that observed groups of patients for several years.

The main outcomes monitored in these trials were specific measures of walking ability, such as the pain-free walking distance and the maximum total distance a person could walk on a standardized test. Short-term research monitored changes measured during the study period in these functional outcomes. However, when multiple smaller trials were analyzed together in systematic reviews, the findings were mixed regarding consistent patterns of change in objective walking distance.

Evidence for use in Acute Ischemic Stroke

Peli was evaluated in studies focusing on episodes where symptoms become more noticeable, specifically in patients who had recently experienced an acute ischemic stroke. The research consists mainly of Randomized Controlled Trials (RCTs), which studies monitored neurological deficits and functional recovery outcomes over time. Research so far indicates patterns related to how patient function evolved, with findings reporting how symptoms evolved in the observed populations. However, the overall evidence is limited by the quality of the studies themselves, with scientific reviews suggesting that trials often had a high or unclear risk of bias.

Long-term Studies and Follow-up Data

The longest follow-up durations for Peli in chronic vascular conditions extend up to a median of approximately three years. These studies primarily monitored long-term clinical events rather than just short-term changes in functional ability. The data describes patterns related to the incidence of cardiovascular and limb-related events over that extended observation period. However, the long-term changes in measured functional walking ability are not fully established.

What is Still Uncertain about the Evidence for Peli

The overall evidence landscape for Peli contributes to understanding symptom patterns but also highlights areas where research is still needed. A key limitation is that the evidence quality varies across studies, leading to mixed findings in certain outcomes. Concerns about publication bias have been noted by researchers. Data for specific groups, such as very older adults or women, remain insufficient to draw broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Peli (FAQ)

Q: How long does the effect of a single dose of Peli typically last?

According to the official product information, the duration of effect depends on the specific formulation used. The oral tablet is designed for continuous, once-daily dosing to maintain a consistent level in the body. The long-acting injectable forms are designed to sustain their effect over a much longer period, with schedules ranging from monthly up to six months.

Q: Is Peli safe to take long-term, according to official information?

Official regulatory documents indicate that the oral formulation of Peli is intended for continuous, long-term administration. As with many medications used for long periods, official safety data cites the potential for certain risks, such as Tardive Dyskinesia, which is a condition that may increase in likelihood with the duration of treatment. The potential for metabolic changes is also noted in long-term regulatory data.

Q: Are there specific vitamins or supplements that are known to interact with Peli?

Official regulatory information specifically lists the herbal product St John's Wort as one to be aware of. This is because it is a strong inducer of certain enzymes that can potentially reduce the amount of Peli in the body. For all other supplements and vitamins, the full interaction profile should be reviewed with a healthcare professional.

Q: What kinds of food or drink should I be aware of when using Peli?

The official prescribing information states that the oral tablet formulation can be taken with or without food. However, regulatory documents consistently advise that alcohol should be avoided while using Peli. This restriction is due to the potential for additive effects on the central nervous system, which may increase certain side effects. The full interaction profile should be reviewed with a healthcare professional.

Q: Is Peli safe for people who are 65 or older?

Regulatory documents indicate that Peli is not approved for use in elderly patients who have psychosis related to dementia, due to an observed increased risk of death. For the general older adult population, official safety data notes a heightened risk for serious neurological and cardiac adverse events. Eligibility and risk are considerations that a healthcare provider should assess on an individual basis.

Q: What is the difference between Peli and a placebo in clinical trials?

Studies and official information indicate that Peli demonstrated efficacy compared to placebo in trials for its approved indications. For certain functional outcomes, however, regulatory reviews note that the findings across various studies can be mixed. This means the measured benefit over a placebo varied depending on the specific study and condition being examined.

Q: How does Peli affect the liver or kidney, according to official data?

Official safety documents place strong emphasis on kidney function, requiring that the dosage be adjusted for patients with renal impairment. The drug's clearance from the body is slower in these individuals, and use is subject to regulatory restriction in cases of severe impairment. In terms of liver function, official reports have noted instances of increased hepatic enzymes and rare cases of jaundice.

Q: What does 'contraindicated' mean in the context of Peli?

In the context of Peli's official labeling, a contraindication is a specific medical situation where the medicine should not be used. This means that a pre-existing condition is present where the potential for harm outweighs any possible benefit of the drug. Contraindications are established in regulatory documents as a measure intended to reduce the risk of serious adverse outcomes.

Q: Are there any major drug classes that should always be avoided with Peli?

Regulatory documents advise caution or avoidance with several classes of drugs based on potential additive effects. This includes medicines that may prolong the QT interval (an electrical activity in the heart), cause excessive low blood pressure (orthostatic hypotension), or lead to increased central nervous system (CNS) effects. Furthermore, strong enzyme inducers (like CYP3A4/P-gp inducers) are subject to regulatory restriction as they can significantly lower Peli's levels.

Q: Can Peli affect a person's ability to drive?

Official documents warn of the potential for cognitive and motor impairment while using Peli. Side effects such as somnolence (sleepiness) and dizziness are reported. Due to these potential risks, the official labeling suggests caution when operating hazardous machinery, including a motor vehicle.

Q: Are there any long-term side effects that official studies have identified?

Regulatory documents identify certain risks that may be associated with long-term administration and require ongoing monitoring. These include the potential for Tardive Dyskinesia, which is a potentially irreversible movement disorder. Other concerns noted in long-term data relate to Metabolic Changes, such as weight gain and increases in blood sugar levels.

Q: Do clinical trials for Peli include a diverse patient population?

Official regulatory reviews have noted limitations regarding the patient populations studied in some clinical trials. Specifically, data for drawing broad conclusions about certain groups, such as very older adults and women, has been reported as insufficient in some studies.

Q: Is it necessary to take Peli at the same time every day?

To help maintain a constant amount of medicine in the blood, regulatory patient information advises taking the oral tablet at the same time each day. Consistency in the daily dosing schedule is advised to support the intended therapeutic effect.

Q: Is Peli a type of antidepressant or anxiety medicine?

The medication is officially classified either as a peripheral vasodilator/vasoactive agent or as an atypical antipsychotic, depending on the formulation and indication. It is not classified as an antidepressant or anxiety medicine in official pharmacological systems.

Q: Is Peli commonly taken with a morning or evening meal?

The standard oral dosing instructions found in the official prescribing information specify that the tablet should be taken each morning. However, the instructions also note that the tablet can be taken with or without food.

Q: Do many people experience the side effect listed as 'dizziness' with Peli?

Regulatory documents report dizziness as a known side effect observed in clinical trials. The specific frequency of this effect can vary, but it is cited in official information as one of the commonly occurring adverse reactions.

Q: Is a headache a common side effect reported for Peli?

Headache is listed as one of the frequently reported side effects in official regulatory documents. As with any side effect, its occurrence and severity can vary among individuals using the medicine.

Q: Is it normal to feel a little nauseous when starting Peli?

Nausea and vomiting are both reported side effects that have been documented in clinical trials. If these feelings occur, they are generally considered common adverse reactions cited in the official labeling.

Q: Can Peli cause weight changes?

Official regulatory information indicates that Peli is associated with weight gain and other metabolic changes observed in clinical trials. Because of this, weight changes are noted as an adverse reaction that requires clinical monitoring.

Q: Is Peli known to cause fatigue or sleepiness?

Official documents report both somnolence (or sleepiness) and fatigue as known side effects of the medication. These are adverse reactions that were observed during the course of clinical trials.

Q: Do I need a special blood test before starting Peli?

Official regulatory information does not explicitly mandate a specific blood test before starting the medication. However, monitoring of certain health markers, such as metabolic changes (e.g., blood sugar) and white blood cell counts, is required during treatment.

Q: Why do some people report feeling nervous or anxious when taking Peli?

Anxiety and nervousness are reported side effects that were observed during clinical trials. When these symptoms occur, they are considered known adverse reactions documented in the official prescribing information.

Q: Is Peli used to treat only the symptoms or the underlying condition?

The drug's mechanism of action is described in official documents as modulating biological systems to address or manage symptoms associated with a condition. For example, it is described as improving peripheral circulation or managing symptoms of psychosis. Official regulatory information does not state that the drug cures or reverses the underlying condition.

Q: Is Peli known to cause stomach problems like diarrhea or constipation?

Official regulatory documents report several gastrointestinal issues as known side effects. Constipation is specifically listed as a common adverse reaction. Other reported effects include nausea, vomiting, and general stomach discomfort.

How should Peli be stored and disposed of?

How to Store and Dispose of Peli

Storage and disposal of Peli (Paliperidone Palmitate injectable suspension) must strictly follow the conditions specified in the official regulatory labeling.


Storage Requirements

  • Temperature: Store the medication at controlled room temperature, specifically 25 C (77 F), with permitted brief excursions between 15 C to 30 C (59 F to 86 F).
  • Prohibited Environment: The product must not be frozen and should be protected from excessive heat and moisture.
  • Handling: The pre-filled syringe must be shaken vigorously for at least 15 seconds immediately before use to ensure a homogeneous suspension.
  • Child Safety: All forms of the medication must be secured out of the sight and reach of children.

Disposal Instructions

  • Sharps Disposal: Used needles and syringes must be immediately discarded into an FDA-cleared sharps disposal container.
  • Unused Product: Any unused or expired medication must be disposed of in compliance with local pharmaceutical waste regulations; the product should not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peli found in:

A-Z Index: